Navacaprant

Navacaprant is a drug that is currently under development for the treatment of osteoarthritis. It is a cannabinoid receptor type 2 (CB2) agonist, which means it binds to and activates the CB2 receptor in the body. This receptor is involved in the regulation of pain and inflammation, making it a potential target for the treatment of conditions like osteoarthritis.

Mechanism of Action

Navacaprant works by binding to and activating the CB2 receptor. This receptor is found primarily on immune cells and is involved in the regulation of immune response and inflammation. By activating this receptor, navacaprant may help to reduce inflammation and pain associated with conditions like osteoarthritis.

Development and Clinical Trials

Navacaprant is currently in the development stage and has not yet been approved for use in humans. It is being developed by the pharmaceutical company Arena Pharmaceuticals. Clinical trials are ongoing to determine the safety and efficacy of this drug in the treatment of osteoarthritis.

Potential Side Effects

As with any drug, there is the potential for side effects with navacaprant. These will be determined through clinical trials. It is important to note that the safety and efficacy of navacaprant have not yet been established.

See Also

• Cannabinoid receptor
• Osteoarthritis
• Arena Pharmaceuticals

Navacaprant Resources
Latest articles Most recent articles Ongoing trials	Wikipedia